These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 22831787)

  • 1. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity.
    Smith MC; Gestwicki JE
    Expert Rev Mol Med; 2012 Jul; 14():e16. PubMed ID: 22831787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
    Ran X; Gestwicki JE
    Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric Modulators of Protein-Protein Interactions (PPIs).
    Ni D; Liu N; Sheng C
    Adv Exp Med Biol; 2019; 1163():313-334. PubMed ID: 31707709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.
    Arkin MR; Tang Y; Wells JA
    Chem Biol; 2014 Sep; 21(9):1102-14. PubMed ID: 25237857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of protein-protein interactions using designed molecules.
    Wilson AJ
    Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
    Ni D; Lu S; Zhang J
    Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmark Study Based on 2P2I
    Wang Z; Kang Y; Li D; Sun H; Dong X; Yao X; Xu L; Chang S; Li Y; Hou T
    J Phys Chem B; 2018 Mar; 122(9):2544-2555. PubMed ID: 29420886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
    Guo W; Wisniewski JA; Ji H
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors.
    Li B; Rong D; Wang Y
    Curr Top Med Chem; 2019; 19(21):1872-1876. PubMed ID: 31696799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Compound Classes: Protein-Protein Interactions.
    Ottmann C
    Handb Exp Pharmacol; 2016; 232():125-38. PubMed ID: 26489828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Druggable protein-protein interactions--from hot spots to hot segments.
    London N; Raveh B; Schueler-Furman O
    Curr Opin Chem Biol; 2013 Dec; 17(6):952-9. PubMed ID: 24183815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.
    Makley LN; Gestwicki JE
    Chem Biol Drug Des; 2013 Jan; 81(1):22-32. PubMed ID: 23253128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based assessment and druggability classification of protein-protein interaction sites.
    Alzyoud L; Bryce RA; Al Sorkhy M; Atatreh N; Ghattas MA
    Sci Rep; 2022 May; 12(1):7975. PubMed ID: 35562538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
    Da Silva F; Bret G; Teixeira L; Gonzalez CF; Rognan D
    J Med Chem; 2019 Nov; 62(21):9732-9742. PubMed ID: 31603323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norstictic Acid Is a Selective Allosteric Transcriptional Regulator.
    Garlick JM; Sturlis SM; Bruno PA; Yates JA; Peiffer AL; Liu Y; Goo L; Bao L; De Salle SN; Tamayo-Castillo G; Brooks CL; Merajver SD; Mapp AK
    J Am Chem Soc; 2021 Jun; 143(25):9297-9302. PubMed ID: 34137598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.
    Sheng C; Dong G; Miao Z; Zhang W; Wang W
    Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
    Wells JA; McClendon CL
    Nature; 2007 Dec; 450(7172):1001-9. PubMed ID: 18075579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?
    Dömling A
    Curr Opin Chem Biol; 2008 Jun; 12(3):281-91. PubMed ID: 18501203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of protein-protein interactions in drug discovery.
    Andrei SA; Sijbesma E; Hann M; Davis J; O'Mahony G; Perry MWD; Karawajczyk A; Eickhoff J; Brunsveld L; Doveston RG; Milroy LG; Ottmann C
    Expert Opin Drug Discov; 2017 Sep; 12(9):925-940. PubMed ID: 28695752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.